Global DNA Sequencing Market 2018-2022
About DNA Sequencing
DNA sequencing is the process of determining the precise order of the four nucleotides, namely, adenine, guanine, cytosine, and thymine, in a strand of DNA.
Technavio’s analysts forecast the global DNA sequencing market to grow at a CAGR of 20.93% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global DNA sequencing market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales DNA sequencing.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global DNA Sequencing Market 2018-2022
Technavio recognizes the following companies as the key players in the global DNA sequencing market: BGI, F. Hoffmann-La Roche, Illumina, Pacific Biosciences of California, and Thermo Fisher Scientific
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is growth of the bioinformatics tools that make DNA sequencing easy. DNA sequencing manufacturers are making measures to increase the affordability and executability of DNA sequencing. Due to this, the next generation sequencing market is witnessing the development of cost-effective and time-effective advanced products. The introduction of cost-effective and easy to handle sequencing bioinformatics DNA sequencing tools will further contribute to the market growth.”
According to the report, one of the major drivers for this market is the all-inclusive cost structure of sequencing products. Manufacturers developed an all-inclusive cost approach, that includes the cost of components, direct costs, and indirect costs. This all-inclusive cost structure explains the cost structure to end-users and funding agencies. Also, this cost approach reduces the volume of sequencing and increase the volume of data. Detailed cost-related data decreases the cost of sequencing and that increases the amount of genome data for better research. Consequently, detailed cost structure is driving the demand for DNA sequencing in the next generation sequencing market.
Further, the report states that one of the major factors hindering the growth of this market is Difficulties in clinical interpretations and inadequate reimbursements. Challenges related to clinical samples can affect the growth of the market. A single exome sample can contain up to 20,000 variants, whereas a whole-genome sample will generally have more than three million. Hence, a patient may have to undergo several genetic tests before the disease-causing mutation is identified. This can become expensive and inconvenient for the patient.
BGI, F. Hoffmann-La Roche, Illumina, Pacific Biosciences of California, and Thermo Fisher Scientific